Wall Street brokerages expect ContraFect Corp (NASDAQ:CFRX) to report earnings per share (EPS) of ($0.10) for the current quarter, according to Zacks. Zero analysts have issued estimates for ContraFect’s earnings, with estimates ranging from ($0.10) to ($0.09). ContraFect reported earnings per share of ($0.15) during the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The company is expected to announce its next earnings report on Wednesday, March 21st.
On average, analysts expect that ContraFect will report full year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.32). For the next financial year, analysts expect that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for ContraFect.
Shares of ContraFect (NASDAQ:CFRX) opened at $1.19 on Wednesday. ContraFect has a 52-week low of $0.80 and a 52-week high of $2.50. The stock has a market capitalization of $86.47, a P/E ratio of -6.26 and a beta of -0.85.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/zacks-analysts-expect-contrafect-corp-cfrx-will-post-earnings-of-0-10-per-share/1821943.html.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.